Galvani Bioelectronics, a clinical-stage company formed through a strategic partnership between GlaxoSmithKline and Verily Life Sciences in 2016 with the aim to develop targeted neuromodulation therapies, announced that the first patient with rheumatoid arthritis was treated through stimulation of the splenic nerve using the its novel bioelectronics platform.

Money

The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers. 

Stimwave LLC received FDA 510(k) clearance for the first wireless, micro-technology neuromodulation device that can enable ongoing full-body MRI scans under certain scanning conditions for the relief of chronic peripheral nerve pain.